The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.
An extended labeling claim has added detection of three additional EGFR mutations to help ID NSCLC patients for whom Boehringer Ingelheim's Gilotrif is indicated.
While the company has historically marketed the test's ability to predict patient drug response, it has more recently focused on its prognostic power.
The trial aims to demonstrate the utility of Biocept's Target Selector PD-L1 assay in patients diagnosed with non-small cell lung cancer.
The company said in April that it planned to launch a test this year but has since decided to take more time to better assess the clinical need and market.
In Cell this week: integrated genomic analysis of adult soft tissue sarcoma, positive selection has greater role in cancer than negative selection, and more.
The WIN Consortium's Catherine Bresson discusses the association's approach for treating cancer patients at the Independent.
The researchers found that most advanced EGFR-mutant lung cancer patients harbored changes in an average of two to three other oncogenes.
A pair of papers point to potential gut microbial contributions to checkpoint blockade immunotherapy response in individuals with lung, kidney, or skin cancer.
The companies plan to develop Thermo's Oncomine Dx Target Test as a companion diagnostic for Blueprint's BLU-667 to identify RET fusions in NSCLC patients.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.